Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing diazepam, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Diazepam is a Schedule IV controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing diazepam are listed in tablet, injection, gel, solution and spray forms. No finished diazepam product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Diazepam is a Schedule IV benzodiazepine that compounding pharmacies prepare by prescription as oral suspensions, rectal preparations and other non-tablet forms.
Diazepam is a long-acting benzodiazepine. It binds to GABA-A receptors in the brain and increases the calming effect of GABA, the main inhibitory neurotransmitter, which reduces anxiety, relaxes skeletal muscle, stops seizures and causes sedation. Manufactured diazepam tablets, oral solution and concentrate are FDA-approved for anxiety disorders and short-term anxiety relief, acute alcohol withdrawal symptoms, as an adjunct for skeletal muscle spasm and spasticity, and as an adjunct in convulsive disorders; injectable and rectal gel forms are also manufactured. A prescriber might order compounded diazepam when a patient needs a strength or liquid that is not manufactured, a dye-free or sugar-free vehicle, or a rectal or topical form in a different base. Compounded preparations are not FDA-approved and require a prescription. Diazepam is a Schedule IV controlled substance under federal law.
Diazepam carries an FDA boxed warning with three parts. First, taking a benzodiazepine with an opioid can cause profound sedation, slowed breathing, coma and death. Second, abuse, misuse and addiction can occur and can lead to overdose or death. Third, continued use causes physical dependence, and stopping suddenly or cutting the dose quickly can trigger withdrawal that includes seizures and can be life-threatening, so never stop without a gradual taper set by your prescriber. Do not drink alcohol, and tell your prescriber about cough or pain medicines, sedating antihistamines, antipsychotics, antidepressants, and drugs like cimetidine, omeprazole, fluoxetine, fluvoxamine or ketoconazole, which can raise diazepam levels. Do not use it if you have myasthenia gravis, sleep apnea, severe breathing or liver problems or acute narrow-angle glaucoma, or in infants under six months. Older adults are more prone to falls, confusion and drug buildup. Call your prescriber right away for trouble breathing, new or worse depression, agitation or thoughts of self-harm. The label says human data do not show a clear link to major birth defects, but that use late in pregnancy can cause a sedated, floppy, poorly feeding newborn or newborn withdrawal, and that breastfeeding is not recommended. LactMed says a single dose usually does not require interrupting breastfeeding, that repeated use calls for watching the infant for sedation, poor feeding and poor weight gain because the drug accumulates, and that other benzodiazepines are preferred. For side effects, talk to your prescriber or pharmacist.
Diazepam is a positive allosteric modulator of GABA-A receptors, increasing chloride channel opening frequency; anxiolysis is attributed to limbic action, muscle relaxation to spinal effects, and sedation and anticonvulsant activity to cortical, thalamic and cerebellar sites. Oral absorption exceeds 90% with peak levels at about 1 to 1.5 hours, delayed by food; protein binding is about 98%, volume of distribution 0.8 to 1.0 L/kg, and metabolism is by CYP2C19 and CYP3A4 to the active metabolite desmethyldiazepam (nordiazepam) plus oxazepam and temazepam. Terminal half-life is about 46 to 48 hours and nordiazepam about 100 hours, so the drug accumulates with repeated dosing and in the elderly or hepatically impaired. Labeled indications: diazepam tablets (Mylan and other generic labelers) for anxiety disorders, acute alcohol withdrawal, adjunctive skeletal muscle spasm and spasticity and adjunctive convulsive disorders. Prescribers have ordered diazepam for short-term spasticity in children with cerebral palsy and for ICU sedation, both listed as off-label by StatPearls. Dosing is per prescriber. Monitor respiratory and cardiovascular status, sedation depth, CBC and liver enzymes with long-term use, and signs of benzodiazepine use disorder with prescription drug monitoring program checks. Diazepam is DEA Schedule IV. Electronic prescribing of controlled substances is voluntary under federal DEA rules; CMS applies a prescriber-level 70 percent threshold for Medicare Part D controlled substance prescriptions; and a number of states mandate EPCS for some or all controlled substances, with state rules controlling where stricter.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
